Peer-reviewedCC BY-NC-ND 4.0eBioMedicine
Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy
Related
- In situ-activated engineered bacteria release combined dual-therapeutic proteins for tumor immunotherapy
- A PD‐L1 Nanobody‐Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC‐I
- Cellular immunotherapy for lung cancer: current clinical evidence, translational challenges, and future perspectives: a narrative review
- Nanomedicine-Enhanced CAR-Engineered Immunotherapy for Lung Cancer: Focusing on Multimodal Strategies and Precision Therapy
- Chimeric antigen receptor-engineered cell therapy for asthma: advances in targeting type 2 inflammation and translational challenges
BibTeX
@article{liu2026senescencetargeted,
title = {{Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy}},
author = {Jiayu Liu and Wenxia Shao and Qing Ye},
journal = {eBioMedicine},
year = {2026},
month = nov,
doi = {10.1016/j.ebiom.2026.106540},
url = {https://linkinghub.elsevier.com/retrieve/pii/S235239642600424X},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Senescence-targeted engineered CAR-T immunotherapy: advances, challenges and perspectives for engineered senolytic immunotherapy
AU - Jiayu Liu
AU - Wenxia Shao
AU - Qing Ye
PY - 2026
DA - 2026/11/10
JO - eBioMedicine
DO - 10.1016/j.ebiom.2026.106540
UR - https://linkinghub.elsevier.com/retrieve/pii/S235239642600424X
SN - 2352-3964
ER -